Plain-English translation of NCT06532812 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two powerful treatments for advanced breast cancer that hasn't responded to standard therapies. First, doctors will extract immune cells called lymphocytes directly from your tumor, grow millions of them in the laboratory, and then put them back into your body. The second part uses (Keytruda), an immunotherapy medication that helps your immune system recognize and fight cancer cells more effectively.
Advanced breast cancer that doesn't respond to standard treatments has very limited options and a poor outlook. This trial exists because researchers believe that combining your own tumor-fighting immune cells with the medication could give patients a new, personalized way to fight their cancer.
You likely qualify if…
You likely don't qualify if…
You will undergo a surgical biopsy or resection to collect immune cells from your tumor. Then you'll receive several medications over about 2 weeks to prepare your body, followed by an infusion of your expanded immune cells on day zero. Over the next few weeks, you'll receive additional infusions of the immunotherapy medication, and you'll have surgery around day 80. After that, you'll continue receiving the immunotherapy medication every 6 weeks for up to a year. Throughout the trial, you'll have regular blood tests, scans, and clinic visits to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China